Cargando…
The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery
PURPOSE: The fibrinogen/albumin ratio (FAR) is increasingly considered as a potential biomarker for predicting prognosis in various malignant tumors, whereas the value of the FAR in predicting the recurrence-free survival (RFS) in patients with combined hepatocellular cholangiocarcinoma (cHCC-CCA) a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143788/ https://www.ncbi.nlm.nih.gov/pubmed/35637941 http://dx.doi.org/10.2147/CMAR.S361462 |
_version_ | 1784715891685982208 |
---|---|
author | Xu, Jiake Li, Shaochun Feng, Ye Zhang, Jie Peng, Youduo Wang, Xiaohong Wang, Hongwei |
author_facet | Xu, Jiake Li, Shaochun Feng, Ye Zhang, Jie Peng, Youduo Wang, Xiaohong Wang, Hongwei |
author_sort | Xu, Jiake |
collection | PubMed |
description | PURPOSE: The fibrinogen/albumin ratio (FAR) is increasingly considered as a potential biomarker for predicting prognosis in various malignant tumors, whereas the value of the FAR in predicting the recurrence-free survival (RFS) in patients with combined hepatocellular cholangiocarcinoma (cHCC-CCA) after surgery has not been studied. PATIENTS AND METHODS: A total of 104 patients with surgical-pathologically proved cHCC-CCA were retrospectively analyzed. The best cut-off value of the FAR was calculated via receiver operating characteristic (ROC) curve analysis, and the cohort was then divided into two groups as high-FAR (H-FAR) group and low-FAR (L-FAR) group. The correlation between the preoperative FAR and clinicopathological characteristics was analyzed. Uni- and multi-variable analyses for RFS were evaluated using a Cox proportional hazards model to verify the predictive value of FAR on the RFS of cHCC-CCA. Additionally, a novel clinical nomogram based on FAR was developed to preoperatively predict the RFS of HCC-CCA. The C-index and calibration were conducted to evaluate the performance of the developed nomogram. RESULTS: According to the cut-off value of the FAR, the patients were grouped into the H-FARI (>0.075) and L-FARI (≤0.075) groups. FAR was significantly correlated with several clinical-pathological features, including age, cirrhosis, AFP, CA19-9, BCLC staging, NLR, and PLR. In the multi-variate analysis, FAR, cirrhosis and tumor size were independent prognostic predictors for poor RFS in cHCC-CCA patients after surgery. Moreover, the clinical nomogram based on FAR was constructed, showing well-predictive accuracy. CONCLUSION: The preoperative FAR is a convenient and feasible serum biomarker for predicting the RFS of cHCC-CCA after surgery. Such developed FAR-based nomogram integrating tumor size and cirrhosis could be served as a feasible and convenient tool to assist the decision-making of clinical strategy. |
format | Online Article Text |
id | pubmed-9143788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-91437882022-05-29 The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery Xu, Jiake Li, Shaochun Feng, Ye Zhang, Jie Peng, Youduo Wang, Xiaohong Wang, Hongwei Cancer Manag Res Original Research PURPOSE: The fibrinogen/albumin ratio (FAR) is increasingly considered as a potential biomarker for predicting prognosis in various malignant tumors, whereas the value of the FAR in predicting the recurrence-free survival (RFS) in patients with combined hepatocellular cholangiocarcinoma (cHCC-CCA) after surgery has not been studied. PATIENTS AND METHODS: A total of 104 patients with surgical-pathologically proved cHCC-CCA were retrospectively analyzed. The best cut-off value of the FAR was calculated via receiver operating characteristic (ROC) curve analysis, and the cohort was then divided into two groups as high-FAR (H-FAR) group and low-FAR (L-FAR) group. The correlation between the preoperative FAR and clinicopathological characteristics was analyzed. Uni- and multi-variable analyses for RFS were evaluated using a Cox proportional hazards model to verify the predictive value of FAR on the RFS of cHCC-CCA. Additionally, a novel clinical nomogram based on FAR was developed to preoperatively predict the RFS of HCC-CCA. The C-index and calibration were conducted to evaluate the performance of the developed nomogram. RESULTS: According to the cut-off value of the FAR, the patients were grouped into the H-FARI (>0.075) and L-FARI (≤0.075) groups. FAR was significantly correlated with several clinical-pathological features, including age, cirrhosis, AFP, CA19-9, BCLC staging, NLR, and PLR. In the multi-variate analysis, FAR, cirrhosis and tumor size were independent prognostic predictors for poor RFS in cHCC-CCA patients after surgery. Moreover, the clinical nomogram based on FAR was constructed, showing well-predictive accuracy. CONCLUSION: The preoperative FAR is a convenient and feasible serum biomarker for predicting the RFS of cHCC-CCA after surgery. Such developed FAR-based nomogram integrating tumor size and cirrhosis could be served as a feasible and convenient tool to assist the decision-making of clinical strategy. Dove 2022-05-23 /pmc/articles/PMC9143788/ /pubmed/35637941 http://dx.doi.org/10.2147/CMAR.S361462 Text en © 2022 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Xu, Jiake Li, Shaochun Feng, Ye Zhang, Jie Peng, Youduo Wang, Xiaohong Wang, Hongwei The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery |
title | The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery |
title_full | The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery |
title_fullStr | The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery |
title_full_unstemmed | The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery |
title_short | The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery |
title_sort | fibrinogen/albumin ratio index as an independent prognostic biomarker for patients with combined hepatocellular cholangiocarcinoma after surgery |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143788/ https://www.ncbi.nlm.nih.gov/pubmed/35637941 http://dx.doi.org/10.2147/CMAR.S361462 |
work_keys_str_mv | AT xujiake thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT lishaochun thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT fengye thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT zhangjie thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT pengyouduo thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT wangxiaohong thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT wanghongwei thefibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT xujiake fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT lishaochun fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT fengye fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT zhangjie fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT pengyouduo fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT wangxiaohong fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery AT wanghongwei fibrinogenalbuminratioindexasanindependentprognosticbiomarkerforpatientswithcombinedhepatocellularcholangiocarcinomaaftersurgery |